**[INVITE** 7/17 NYC Expert Lunch on Psychedelics - CMPS DFTX ATAI HELP GHRS LLY

Research evidence excerpt

**[INVITE** 7/17 NYC Expert Lunch on Psychedelics - CMPS DFTX ATAI HELP GHRS LLY

Expert

Series

USA | Biotechnology EquityJulyResearch16, 2026

**INVITE** 7/17 NYC Expert Lunch on

Psychedelics - CMPS DFTX ATAI HELP GHRS

LLY

On July 17 (tomorrow), we are hosting a 12pm ET lunch in NYC with a

psychiatrist to discuss: (1) Current use of JNJ Spravato in TRD depression

(~$2B annual runrate), (2) CMPS' COMP360 (psilocybin) pot'l 2027 adoption

curve in TRD, assuming YE:26/early 2027 approval, (3) Impressions of DFTX's

DT120 (LSD) (+) Phase III MDD data, (4) Other psychedelics in late-stage

development (ATAI, HELP, etc), (5) Overall drivers to ensure the successful

launch of psychedelics.

.

Friday, July 17, 2026, at 12:00pm ET in New York City

Please contact us or your sales rep for info/registration.•

Hosted by Andrew Tsai, TsaiBiotech@jefferies.com•

Relevant Tickers: DFTX, ATAI, CMPS, HELP, JNJ, LLY•

Discussion topics:

(1) Expected applicability of Spravato's 7,500+ site infrastructure for incoming psychedelic

treatments

Overview of Spravato (intranasal esketamine) and how it is delivered in practice, current•

bottlenecks, clinic economics (e.g., reimbursement, throughput, margins, etc), and barriers to

broader adoption

Intent to adopt psychedelics in MDD and TRD, and anticipated similarities and differences to•

the current interventional psychiatry model

Value of both short- and long-duration interventional psychedelic treatments, and the•

importance of real-world dosing frequency

Expected reimbursement and real-world staffing requirements for drug administration and Andrew Tsai * | Equity Analyst•

monitoring for novel psychedelics +1 (415) 229-1566 | atsai@jefferies.com

Implications of DEA scheduling and REMS program requirements Brian Balchin, ACA * | Equity Analyst•